Spironolactone vs ARNI in HFrEF Dialysis Patients
In dialysis patients with HFrEF, sacubitril/valsartan (ARNI) should be preferred over spironolactone based on emerging real-world evidence showing mortality benefit and superior safety profile in this specific population.
Rationale and Evidence Hierarchy
The standard HFrEF guidelines 1, 2 universally recommend both MRAs (Class I, Level A) and ARNIs (Class I, Level B) for symptomatic HFrEF patients. However, these landmark trials explicitly excluded dialysis patients, creating a critical evidence gap. The 2022 AHA/ACC/HFSA guidelines 1 recommend MRAs only when eGFR >30 mL/min/1.73m² and potassium <5.0 mEq/L—criteria that dialysis patients cannot meet by definition.
Why ARNI is Preferred in Dialysis
Recent dialysis-specific evidence strongly favors ARNI:
Mortality benefit: A 2024 propensity-matched study of 2,868 hemodialysis patients 3 demonstrated that sacubitril/valsartan reduced all-cause mortality (HR 0.82,95% CI 0.73-0.92) and all-cause hospitalization (HR 0.86,95% CI 0.79-0.93) compared to ACEi/ARB therapy.
Long-term outcomes: Patients on sacubitril/valsartan for ≥9 months showed significantly lower 5-year mortality (39.3% vs 54.7%, HR 0.46, P=0.0094) 4.
Cardiac function improvement: LVEF improved by 14.51±18.98% with ARNI versus 6.91±18.44% without ARNI at 3 years (P=0.0408) 4. Multiple studies 5, 6 confirmed significant LVEF improvements and NYHA class reduction.
Superior safety profile: Critically, ARNI showed reduced hyperkalemia risk (HR 0.71,95% CI 0.62-0.81) 3 compared to ACEi/ARB, with no increased hypotension risk (HR 0.99,95% CI 0.83-1.19).
Why Spironolactone is Problematic in Dialysis
Spironolactone carries substantial risks in dialysis patients:
The RALES trial 7 that established spironolactone's mortality benefit excluded patients with creatinine >2.5 mg/dL or potassium >5.0 mEq/L—criteria that exclude virtually all dialysis patients.
Guidelines 1, 8 explicitly warn about hyperkalemia risk with MRAs, requiring frequent potassium monitoring (at 1,4,8,12 weeks initially) 8. Dialysis patients have inherently unstable potassium levels between treatments.
The 2016 ESC guidelines 2 specifically warn against combining ARB with MRA due to "increased risk of renal dysfunction and hyperkalaemia" (Class III, Level C).
No robust evidence exists demonstrating spironolactone's safety or efficacy specifically in dialysis-dependent HFrEF patients.
Practical Implementation Algorithm
For dialysis patients with HFrEF:
Initiate sacubitril/valsartan at 24/26 mg twice daily (lower than standard 49/51 mg starting dose given dialysis status) 9
Titration schedule: Increase dose every 2-4 weeks as tolerated, targeting 97/103 mg twice daily 9. Most dialysis patients in studies received lower doses (median 100-400 mg/day total) 5, 6, with only 14% reaching maximum dose 3.
Monitor closely: Blood pressure pre- and post-dialysis, potassium levels (though ARNI reduces hyperkalemia risk), and symptoms
Avoid spironolactone unless ARNI is contraindicated (angioedema history) or absolutely not tolerated despite dose reduction
If spironolactone must be used: Start 25 mg on alternate days (not daily), check potassium at 1,4,8,12 weeks 8, and maintain extreme vigilance for hyperkalemia (>6.0 mEq/L requires immediate discontinuation)
Critical Caveats
Evidence quality: All ARNI data in dialysis patients comes from observational studies [10-11], not RCTs. A 2026 meta-analysis 12 acknowledges these findings "remain susceptible to residual confounding and should not be interpreted as demonstrating causal treatment effects."
Dosing reality: Most dialysis patients tolerate lower ARNI doses than standard HFrEF populations 3, 5, 6
Washout period: If switching from ACEi, allow 36-hour washout before starting ARNI 9 to prevent angioedema
Contraindications: Both drugs are contraindicated in pregnancy 9; ARNI carries angioedema risk similar to ACEi
The convergence of mortality benefit, cardiac function improvement, and paradoxically lower hyperkalemia risk makes ARNI the rational first choice over spironolactone in dialysis-dependent HFrEF patients, despite the absence of RCT data in this excluded population.